| 20th Mar 2026 11:00 am |
RNS |
Notification of Admission of Shares |
| 16th Mar 2026 7:00 am |
RNS |
Imfinzi approved in EU for early gastric cancer |
| 16th Mar 2026 7:00 am |
RNS |
Imfinzi approved in EU for early gastric cancer |
| 10th Mar 2026 11:00 am |
RNS |
Notice of AGM |
| 10th Mar 2026 11:00 am |
RNS |
Notice of AGM |
| 6th Mar 2026 11:10 am |
RNS |
Director/PDMR Shareholding |
| 6th Mar 2026 11:05 am |
RNS |
Director/PDMR Shareholding |
| 6th Mar 2026 11:00 am |
RNS |
Director/PDMR Shareholding |
| 2nd Mar 2026 3:00 pm |
RNS |
Total Voting Rights |
| 26th Feb 2026 7:00 am |
RNS |
AstraZeneca prices a $2bn bond offering |
| 25th Feb 2026 7:00 am |
RNS |
Filing of Form 20-F with SEC |
| 24th Feb 2026 11:00 am |
RNS |
Annual Financial Report |
| 24th Feb 2026 7:00 am |
RNS |
Directorate change |
| 20th Feb 2026 7:00 am |
RNS |
Fixed-duration Calquence combo approved in US |
| 10th Feb 2026 7:00 am |
RNS |
Final Results |
| 3rd Feb 2026 7:00 am |
RNS |
Update on Saphnelo subcutaneous administration |
| 2nd Feb 2026 3:00 pm |
RNS |
Total Voting Rights |
| 2nd Feb 2026 7:05 am |
RNS |
Imfinzi recommended in EU for early gastric cancer |
| 2nd Feb 2026 7:00 am |
RNS |
AstraZeneca begins trading on NYSE |
| 30th Jan 2026 7:00 am |
RNS |
AstraZeneca agrees obesity and T2D deal with CSPC |
| 29th Jan 2026 9:51 am |
RNS |
AstraZeneca invests $15bn in China through 2030 |
| 20th Jan 2026 7:00 am |
RNS |
AstraZeneca to complete direct listing on NYSE |
| 8th Jan 2026 7:00 am |
RNS |
AZN new Head of Investor Relations Joris Silon |
| 2nd Jan 2026 3:00 pm |
RNS |
Total Voting Rights |
| 22nd Dec 2025 11:00 am |
RNS |
Director/PDMR Shareholding |
| 22nd Dec 2025 11:00 am |
RNS |
Director/PDMR Shareholding |
| 22nd Dec 2025 7:30 am |
RNS |
Enhertu granted BTD for post-neoadjuvant early BC |
| 22nd Dec 2025 7:30 am |
RNS |
Enhertu granted BTD for post-neoadjuvant early BC |
| 22nd Dec 2025 7:00 am |
RNS |
Update on LATIFY Phase III trial of ceralasertib |
| 22nd Dec 2025 7:00 am |
RNS |
Update on LATIFY Phase III trial of ceralasertib |
| 19th Dec 2025 11:00 am |
RNS |
Director/PDMR Shareholding |
| 19th Dec 2025 11:00 am |
RNS |
Director/PDMR Shareholding |
| 16th Dec 2025 7:05 am |
RNS |
Subcutaneous Saphnelo approved in EU |
| 16th Dec 2025 7:00 am |
RNS |
Enhertu approved in US for 1L HER2+ metastatic BC |
| 4th Dec 2025 3:00 pm |
RNS |
Holding(s) in Company |
| 1st Dec 2025 3:05 pm |
RNS |
Block listing Interim Review |
| 1st Dec 2025 3:00 pm |
RNS |
Total Voting Rights |
| 26th Nov 2025 7:00 am |
RNS |
Imfinzi approved in US for early gastric cancer |
| 24th Nov 2025 7:00 am |
RNS |
AstraZeneca manufacturing investment in Maryland |
| 20th Nov 2025 7:00 am |
RNS |
Koselugo (selumetinib) approved in the US |
